

Press Release

Zug, 1 April 2011

HBM BioVentures: Successful sale of indirect holding in China Health System generates cash inflow of approximately USD 27 million

- BioVeda China, a fund in the HBM BioVentures portfolio, has successfully sold its investment in China Health System.
- The sale increases HBM BioVentures' net asset value (NAV) by CHF 1.00 per share.

BioVeda China L.P., a fund in HBM BioVentures Ltd.'s portfolio (SIX: HBMN), sold its portfolio company China Health System Ltd. yesterday to Shanghai Pharmaceuticals Holding. BioVeda China realised a multiple of 14 times its invested capital on the sale and, after this sale, continues to hold one significant and three smaller investments.

HBM BioVentures is a founding partner and the largest investor in BioVeda China, which was set up in 2005 to invest in the People's Republic of China. As part of its active involvement in the fund, in 2006 HBM BioVentures increased its investment from USD 5.0 million to USD 8.5 million (34% of the fund). At closing of the sale of China Health System by BioVeda China HBM BioVentures will receive approximately USD 27 million (CHF 25 million) in cash. The sale of this single company in the BioVeda China portfolio represents a return for HBM BioVentures of 3.2 times its total investment in the BioVeda China fund, and raises the net asset value (NAV) of HBM BioVentures last published by CHF 1.00 per share.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, Tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

HBM BioVentures Ltd

As a venture capital company, HBM BioVentures invests world-wide in some 30 mature young companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies. Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN). Visit www.hbmbioventures.com.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com